Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
An 8-week attention training programme using brain-computer interface (BCI) can help improve inattentive symptoms in children with attention deficit hyperactivity disorder (ADHD), thus providing a potential nonpharmacologic option for treating ADHD, a local study finds.
A novel device for trigeminal nerve stimulation (TNS) effectively improves attention deficit hyperactivity disorder (ADHD) symptoms in children aged 8–12 years, providing a safe nonmedication approach to treating ADHD, a recent study shows.
Use of memantine in the treatment of adults with attention deficit hyperactivity disorder (ADHD) appears to reduce symptoms associated with the condition, in addition to having a tolerable safety profile, a study has shown.
Preschoolers are likely to follow an unhealthy dietary pattern, and patterns high in processed food and snacks contribute to an increased risk of attention-deficit/hyperactivity disorder (ADHD), whereas a pattern high in vegetables exerts a protective effect, according to a study from China.
Individuals with attention-deficit hyperactivity disorder (ADHD) who are treated with atomoxetine or methylphenidate may have a risk for elevated heart rate and systolic blood pressure (BP), according to a meta-analysis.
Individuals with attention deficiency hyperactivity disorder (ADHD) or anxiety are at greater risk of developing bipolar disorder, according to a study. Moreover, the risk further increases in those who have received diagnoses of both ADHD and anxiety.
A substantial number of patients with gambling addiction screen positive for attention-deficit/hyperactivity disorder (ADHD), according to a Singapore study. Furthermore, these patients have lower levels of gambling-related cognitions, suggesting that their gambling behaviour is rather guided by impulsivity.
Youths treated with a 12-week course of either olanzapine, risperidone, or aripiprazole may have an increased risk for elevated adiposity and decreased insulin sensitivity, according to a recent study.
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.